PTGX Live signals | Maximize Profits with Getagraph.com

BUY 93206 min ago

@ $27.66

Issued: 14 Feb 2024 @ 13:56

Return: -8.80%

Previous signal: Feb 14 - 09:30

Previous signal: Sell

Return: 0.75 %

Live Chart Being Loaded With Signals

Commentary (18 Apr 2024 @ 16:00):

Stats
Today's Volume	365 868
Average Volume	693 704
Market Cap	1.47B
EPS	$0 ( 2024-03-20 )
Next earnings date	( $2.51 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-18.14
ATR14	$0.0190 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Patel Dinesh V Ph D	Sell	25 000	Common Stock
2024-03-07	Selick Harold E	Buy	6 490	Common Stock
2024-03-07	Selick Harold E	Sell	6 490	Stock Option (right to buy)
2024-03-01	Patel Dinesh V Ph D	Sell	30 000	Common Stock
2024-03-01	Waddill William D.	Buy	12 975	Common Stock

INSIDER POWER
67.09
Last 96 transactions
Buy: 2 575 390 \| Sell: 455 691

Volume Correlation

Long: -0.40 (neutral)

Short: -0.49 (neutral)

Signal:(33.847) Neutral

Protagonist Therapeutics Correlation

10 Most Positive Correlations
ITAQU	0.969
PLYA	0.949
MCAA	0.937
BRLI	0.932
PANL	0.929
IOAC	0.927
RNXT	0.925
MLTX	0.923
RIVE	0.923
ALTR	0.92

10 Most Negative Correlations
LMPX	-0.928
AROW	-0.921
JAGX	-0.921
ONEM	-0.915
PSHG	-0.91
RPRX	-0.908
GNTY	-0.908
BWB	-0.907
CSSEP	-0.906
BLUE	-0.901

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Protagonist Therapeutics Correlation - Currency/Commodity

-0.27
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.18
( neutral )

-0.24
( neutral )

0.11
( neutral )

Protagonist Therapeutics Financials

Annual	2023
Revenue:	$60.00M
Gross Profit:	$56.69M (94.48 %)
EPS:	$-1.390

Q4	2023
Revenue:	$60.00M
Gross Profit:	$59.17M (98.61 %)
EPS:	$0.450

Q3	2023
Revenue:	$0
Gross Profit:	$-827 000 (0.00 %)
EPS:	$-0.580

Q2	2023
Revenue:	$0
Gross Profit:	$-821 000 (0.00 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Protagonist Therapeutics

Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.